Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance.
Li MM, Baranwal A, Gurney M, Shah SN, Al-Kali A, Alkhateeb HB, Foran JM, Arana-Yi C, Ongie L, Chen D, Mangaonkar AA, McCullough K, Tefferi A, Lasho TL, Finke CM, Patnaik MM, Shah MV. Li MM, et al. Among authors: mangaonkar aa. Blood Adv. 2024 Apr 2:bloodadvances.2023012357. doi: 10.1182/bloodadvances.2023012357. Online ahead of print. Blood Adv. 2024. PMID: 38564774
Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms.
Alkhateeb HB, Nanaa A, Viswanatha D, Foran JM, Badar T, Sproat L, He R, Nguyen P, Jevremovic D, Salama ME, Greipp P, Gangat N, Tefferi A, Litzow MR, Mangaonkar AA, Shah MV, Patnaik M, Al-Kali A. Alkhateeb HB, et al. Among authors: mangaonkar aa. Blood Adv. 2022 Jan 25;6(2):528-532. doi: 10.1182/bloodadvances.2021005738. Blood Adv. 2022. PMID: 34644397 Free PMC article.
Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms.
Shah MV, Mangaonkar AA, Begna KH, Alkhateeb HB, Greipp P, Nanaa A, Elliott MA, Hogan WJ, Litzow MR, McCullough K, Tefferi A, Gangat N, Patnaik MM, Al-Kali A, He R, Chen D. Shah MV, et al. Among authors: mangaonkar aa. Blood Cancer J. 2022 Jul 8;12(7):106. doi: 10.1038/s41408-022-00703-8. Blood Cancer J. 2022. PMID: 35803921 Free PMC article.
Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts.
Mangaonkar AA, Lasho TL, Finke CM, Gangat N, Al-Kali A, Elliott MA, Begna KH, Alkhateeb H, Wolanskyj-Spinner AP, Hanson CA, Ketterling RP, Hogan WJ, Pardanani A, Litzow MR, Tefferi A, Patnaik MM. Mangaonkar AA, et al. Blood Cancer J. 2018 Feb 12;8(2):18. doi: 10.1038/s41408-018-0051-1. Blood Cancer J. 2018. PMID: 29434284 Free PMC article. No abstract available.
Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.
Coston T, Pophali P, Vallapureddy R, Lasho TL, Finke CM, Ketterling RP, Carr R, Binder M, Mangaonkar AA, Gangat N, Al-Kali A, Litzow M, Zblewski D, Pardanani A, Tefferi A, Patnaik MM. Coston T, et al. Among authors: mangaonkar aa. Am J Hematol. 2019 Jul;94(7):767-779. doi: 10.1002/ajh.25488. Epub 2019 May 3. Am J Hematol. 2019. PMID: 30964202 Free article. Clinical Trial.
Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia.
Mangaonkar AA, Reichard KK, Binder M, Coltro G, Lasho TL, Carr RM, Chiu A, Negron V, Hefazi M, Anagnostou T, Timm MM, Hiebert JW, Villasboas JC, Gonsalves WI, Gangat N, Shah M, Alkhateeb HB, Al-Kali A, Elliott MA, Begna KH, Wolanskyj-Spinner AP, Litzow MR, Hogan WJ, Ansell SM, Pardanani A, Tefferi A, Patnaik MM. Mangaonkar AA, et al. Blood Adv. 2020 Nov 10;4(21):5425-5430. doi: 10.1182/bloodadvances.2020002415. Blood Adv. 2020. PMID: 33152058 Free PMC article.
122 results